A Phase I/II Open-Label Trial of CPI-613� devimistat plus Hydroxychloroquine to Evaluate Maximally Tolerated Dose MTD, Safety and Efficacy in Patients with Relapsed or Refractory Clear Cell Sarcoma CCS

Brief Summary

Type:
Sarcomas

Study Type:
Treatment

Phase:
I/II

ClinicalTrials.gov Identifier:
NCT04593758

Study #:
STUDY00148473

Start Date:
Jun 19, 2022

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04593758

View Complete Trial Details & Eligibility at ClinicalTrials.gov